Formica CA, Cosman F., Nieves J., Herbert J., Lindsay R.Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoidUse Calcif Tissue Int1997; 61: 129-33.
2.
Weinstock-Guttman B., Gallagher E., Baier M., Green L., Feichter J., Patrick K. et al. Risk of bone loss in men with multiple sclerosis. Mult Scler2004; 10: 170-5.
3.
Lacey DL, Timms E., Tan HL, Kelley MJ, Dunstan CR, Burgess T. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell1998; 93: 165-76.
4.
Hofbauer LCOsteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur j endokrinol1999; 141: 195-210.
5.
Browner WS, Lui LY, Cummings SRAssociations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab2001; 86: 631-7.
6.
Kong YY, Boyle WJ, Penninger JMOsteoprotegerin ligand: a regulator of immune responses and bone physiology . Immunol Today2000; 21: 495-502.
7.
Hofbauer LC, Cepok S., Hemmer B.Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid . Acta Neuropathol (Berl)2004; 107: 575-7.
8.
Weinstock-Guttman B., Hong J., Santos R., Tamano-Blanco M., Badgett D., Patrick K. et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients . Mult Scler2006; 12: 541-50.
9.
Peter JB, Boctor FN, Tourtellotte WWSerum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology1991; 41: 121-3.
10.
Imamura K., Hayashi F., Suzumura A.[Cytokine production by peripheral blood monocytes/macrophages in the patients with multiple sclerosis and its suppression by methylprednisolone]Rinsho Shinkeigaku1992; 32: 276-80.
